(Q50528317)

English

Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.

scientific article published on 9 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

author name string

Akizuki Morikawa

1

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Kanaki Ishizeki

2

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Yasunori Iwashima

3

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Hiroki Yokoyama

4

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Eiji Muto

5

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Eiji Oshima

6

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Masatomo Sekiguchi

7

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Takanori Miura

8

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Hiroshi Itoh

9

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Masakazu Haneda

10

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

publication date

9 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Clinical and experimental nephrology

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

15

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

6

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

848-853

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

https://scigraph.springernature.com/pub.10.1007/s10157-011-0512-3

0 references

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Revised equations for estimated GFR from serum creatinine in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Anti-inflammatory effect of PPARgamma in cultured human mesangial cells

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Angiotensin inhibition stimulates PPARgamma and the release of visfatin

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0512-3

21 January 2018

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

1 reference

https://pubmed.ncbi.nlm.nih.gov/21823043

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21823043

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/21823043

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/21823043

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21823043

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21823043

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10157-011-0512-3

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/21823043

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50528317&oldid=1410394792"